Clinical trials: Therapy-Resistant Depression
Treatment Resistant Depression
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
- Trial name
- NCT05144789
- Testing
- Active TBS-DLPFC, Active TBS-DMPFC
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Major Depressive Disorder
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression
Electroconvulsive therapy (ECT), is considered the most effective treatment for severe treatment resistant major depressive disorder (MDD), but it requires about 3 weeks of treatments and can cause considerable acute deficits in…
- Trial name
- NCT01260649
- Testing
- ketamine, IV Saline, ECT
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depressive Disorder
Ketamine for Treatment Resistant Late-Life Depression
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine…
- Trial name
- NCT02556606
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression, Electroconvulsive Therapy
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as…
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine
- Trial name
- ELEKT-D (NCT03113968)
- Testing
- electroconvulsive therapy (ECT), Ketamine
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Bo Hu
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Depression, Depressive Disorder
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Treatment-resistant, Depressive Disorder, Major
- Trial name
- NCT02452892
- Testing
- LFMS
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Tal Medical, Inc.
Treatment Resistant Depression
Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study
This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.
- Trial name
- NCT03680781
- Testing
- Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC, Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Depression
Ketamine Plus Lithium in Treatment-Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant…
- Trial name
- NCT01880593
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Treatment Resistant Depression
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and…
- Trial name
- NCT05414422
- Testing
- PCN-101
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 102 people
- Sponsor
- Perception Neuroscience
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Obesity, Morbid, Insulin Resistance
Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients
More and more people in Canada and around the world are severely (morbidly) obese, and this is associated with a high risk for poor blood sugar control (insulin resistance, IR) and diabetes.
- Trial name
- NCT02970877
- Testing
- Fecal filtrate from 150 g stool from healthy lean donors, Fecal filtrate from 150 g of the recipient's own stool
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Johane Allard
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Treatment Resistant Depression
Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
This study will be an open-label 6-week (30 session) trial of active repetitive transcranial magnetic stimulation (rTMS) using a fixed frequency (10 Hz) but varying stimulation intensities using a 3+3 study design for safety and…
- Trial name
- NCT02611206
- Testing
- Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota